The effects of Omega 3 fatty acid supplements on treatment of type 2 diabetes complications

The assessment of the effect of omega 3 fatty acids supplementation on serum Irisin, BDNF (Brain Derived Neurotrophic Factor) and Myonectin in Patients with diabetes type 2 disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015061922769N3

Enrollment

Registered

2015-08-16

Start date

2015-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes type 2. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention group: omega-3 polyunsaturated fatty acid supplements at a dose of 3750 mg per day (1250 mg per capsule of omega-3 polyunsaturated fatty acid is containing (EPA = 600mg, D

Treatment - Drugs

Intervention group: omega-3 polyunsaturated fatty acid supplements at a dose of 3750 mg per day (1250 mg per capsule of omega-3 polyunsaturated fatty acid is containing (EPA = 600mg, DHA = 300 mg).)

Control group: placebo or (paraffin oral) at a dose of 3750 mg per day

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: diabetics men and women aged 30-65 years old, ; BMI in the range of 35-25 BMI ranged 25-35; the desire to maintain weight during the study weight maintenance tendency during the study; the tendency to maintain normal activities during the current life style tendency to keep current life style and activities during the study; willingness to cooperate in the project Exclusion criteria: changing on the dose or types of diabetes medications; inflammatory disease given; unwillingness to continue the cooperation; taking ten percent supplement non using ten or more percent of the supplements; any allergic reactions to omega-3 components

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Irisin. Timepoint: The beginning and end of the study (before and after intervention). Method of measurement: ELISA.;Myonectin. Timepoint: The beginning and end of the study (before and after intervention). Method of measurement: ELISA.;BDNF(Brain Derived Neurotrophic Factor). Timepoint: The beginning and end of the study (before and after intervention). Method of measurement: ELISA.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Hasan Javanbakht

School of Nutritional Sciences & Dietetics,Tehran University of Medical Sciences

mhjavan@sina.tums.ac.ir; mhjavan2001@yahoo.com; samaneh_ansari68@yahoo.com00

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026